---
title: "OTLK.US (OTLK.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OTLK.US/news.md"
symbol: "OTLK.US"
name: "OTLK.US"
parent: "https://longbridge.com/en/quote/OTLK.US.md"
datetime: "2026-06-14T01:35:28.509Z"
locales:
  - [en](https://longbridge.com/en/quote/OTLK.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OTLK.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OTLK.US/news.md)
---

# OTLK.US (OTLK.US) — Related News

### [Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session](https://longbridge.com/en/news/289595240.md)
*2026-06-12T12:02:06.000Z*
> Lennar Corp shares fell 2.7% in pre-market trading after reporting mixed Q2 results: adjusted EPS of $1.31 beat estimate

### [12 Health Care Stocks Moving In Wednesday's Intraday Session](https://longbridge.com/en/news/289359849.md)
*2026-06-10T17:05:47.000Z*
> During Wednesday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Inda

### [Tuesday 6/2 Insider Buying Report: HOOD, OTLK](https://longbridge.com/en/news/288445079.md)
*2026-06-02T14:40:29.000Z*
> Insider buying reports for Tuesday, June 2 highlight significant purchases at Robinhood Markets (HOOD) and Outlook Thera

### [Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) | OTLK Stock News](https://longbridge.com/en/news/288276749.md)
*2026-06-01T04:46:00.000Z*
> Outlook Therapeutics announced the resubmission of its Biologics License Application (BLA) to the U.S. FDA for ONS-5010/

### [Outlook Therapeutics sells 8.54M shares in registered direct offering to GMS Ventures](https://longbridge.com/en/news/288114626.md)
*2026-05-29T20:33:01.000Z*
> Outlook Therapeutics completed a registered direct offering, selling approximately 8.54 million common shares to GMS Ven

### [Outlook Therapeutics Prices $5 Million Registered Direct Offering](https://longbridge.com/en/news/288026013.md)
*2026-05-29T07:15:21.000Z*
> Outlook Therapeutics, Inc. has priced a $5 million registered direct offering of 8,539,709 shares at $0.5855 each to its

### [Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest](https://longbridge.com/en/news/288021336.md)
*2026-05-29T06:33:52.000Z*
> SciSparc (SPRC) gained regulatory approval to acquire a 54% stake in CliniQuantum, boosting its shares by nearly 140%. C